We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Paratek Pharmaceuticals announced that a pre-emergency use authorization (EUA) application for NUZYRA (omadacycline) has been submitted to the U.S. Food and Drug Administration (FDA).